Westwood Holdings Group Inc. Sells 30,473 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Westwood Holdings Group Inc. lessened its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 67.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,859 shares of the company’s stock after selling 30,473 shares during the period. Westwood Holdings Group Inc.’s holdings in CRISPR Therapeutics were worth $1,013,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of CRSP. Blue Trust Inc. bought a new position in shares of CRISPR Therapeutics in the 4th quarter valued at about $32,000. Bourgeon Capital Management LLC grew its holdings in CRISPR Therapeutics by 1,000.0% during the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock worth $34,000 after purchasing an additional 500 shares during the period. Riggs Asset Managment Co. Inc. grew its holdings in CRISPR Therapeutics by 66.7% during the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock worth $34,000 after purchasing an additional 200 shares during the period. Principal Securities Inc. bought a new position in CRISPR Therapeutics during the fourth quarter worth about $41,000. Finally, NBC Securities Inc. grew its holdings in CRISPR Therapeutics by 257.6% during the first quarter. NBC Securities Inc. now owns 608 shares of the company’s stock worth $41,000 after purchasing an additional 438 shares during the period. Institutional investors own 69.20% of the company’s stock.

Analysts Set New Price Targets

CRSP has been the subject of a number of research analyst reports. Guggenheim reiterated a “neutral” rating on shares of CRISPR Therapeutics in a report on Friday, June 28th. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Piper Sandler reiterated an “overweight” rating and set a $105.00 price target on shares of CRISPR Therapeutics in a report on Monday, June 17th. Needham & Company LLC reiterated a “buy” rating and set a $88.00 price target on shares of CRISPR Therapeutics in a report on Thursday, June 27th. Finally, Robert W. Baird raised their price objective on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the stock a “neutral” rating in a research report on Thursday, May 9th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, CRISPR Therapeutics presently has an average rating of “Hold” and a consensus price target of $76.67.

Insider Activity at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $56.09, for a total value of $188,798.94. Following the transaction, the chief operating officer now directly owns 6,745 shares of the company’s stock, valued at $378,327.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ CRSP traded down $3.74 during midday trading on Friday, reaching $51.11. The company’s stock had a trading volume of 2,557,314 shares, compared to its average volume of 1,300,299. CRISPR Therapeutics AG has a fifty-two week low of $37.55 and a fifty-two week high of $91.10. The business’s 50 day moving average price is $57.20 and its two-hundred day moving average price is $63.25. The company has a market cap of $4.34 billion, a P/E ratio of -18.79 and a beta of 1.70.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.08). The firm had revenue of $0.50 million for the quarter, compared to the consensus estimate of $25.53 million. The company’s quarterly revenue was down 99.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.67) EPS. Sell-side analysts forecast that CRISPR Therapeutics AG will post -5.52 earnings per share for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.